Pfizer Says Litfulo Improves Facial, Total Body Repigmentation in Vitiligo Studies

12:15 PM EDT, 10/02/2026 (MT Newswires) -- Pfizer (PFE) said its oral treatment Litfulo led to significant facial and total body repigmentation in two phase 3 studies of adults with nonsegmental vitiligo, a chronic condition marked by the loss of pigment-producing cells. Continuous improvements began at week 24 and increased through week 52, the company said Friday in a report. Litfulo is taken once daily. Pfizer said about 22% of patients receiving the 100 mg dose achieved at least a 75% improvement in facial repigmentation compared with about 2% on placebo, while 13% reached at least a 50% improvement in total body repigmentation versus about 2% on placebo. With the 50 mg dose, roughly 12% achieved the facial endpoint and about 9% reached the total body endpoint, compared with about 2% on placebo for each measure. The safety profile was consistent with Litfulo's established profile in alopecia areata, with no new safety signals reported, the company said. Pfizer said it plans to submit the data to global regulators, including the US Food and Drug Administration and European Medicines Agency. Price: 27.46, Change: -0.66, Percent Change: -2.35